1IA
PVLA

1620 Investment Advisors’s Palvella Therapeutics PVLA Stock Holding History

1620 Investment Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-55
Closed -$318K – 154
2023
Q4 		$318K Buy
+55
New +$1.01K 0.35% 97

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

1620 Investment Advisors's PVLA Position: Q1 2024 in Review

1620 Investment Advisors sold out of Palvella Therapeutics (PVLA) in Q1 2024, closing a stake of 55 shares — an estimated $318K sold.

1620 Investment Advisors first reported a position in PVLA in Q4 2023 and held it in 1 quarter. The position peaked at $318K in Q4 2023. 41 funds tracked by Wall St. Rank hold PVLA as of Q1 2024.

  • 1620 Investment Advisors reported no remaining Palvella Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 1620 Investment Advisors sold 55 Palvella Therapeutics shares in Q1 2024, an estimated $318K.
  • 1620 Investment Advisors first reported a position in Palvella Therapeutics in Q4 2023 and held it in 1 quarter.
  • 1620 Investment Advisors's Palvella Therapeutics position peaked at $318K in Q4 2023.
  • 41 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2024.

Based on 1620 Investment Advisors's 13F filing for Q1 2024, filed 13 May 2024.